These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2541225)

  • 21. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses.
    Badger J; Minor I; Oliveira MA; Smith TJ; Rossmann MG
    Proteins; 1989; 6(1):1-19. PubMed ID: 2558377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance.
    Basta HA; Ashraf S; Sgro JY; Bochkov YA; Gern JE; Palmenberg AC
    Virology; 2014 Jan; 448():82-90. PubMed ID: 24314639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theoretical studies of viral capsid proteins.
    Phelps DK; Speelman B; Post CB
    Curr Opin Struct Biol; 2000 Apr; 10(2):170-3. PubMed ID: 10753813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
    Speelman B; Brooks BR; Post CB
    Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.
    Diana GD; Treasurywala AM; Bailey TR; Oglesby RC; Pevear DC; Dutko FJ
    J Med Chem; 1990 May; 33(5):1306-11. PubMed ID: 2158559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program.
    Andries K; Dewindt B; Snoeks J; Willebrords R; Stokbroekx R; Lewi PJ
    Antiviral Res; 1991 Oct; 16(3):213-25. PubMed ID: 1666824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based drug design of antirhinoviral compounds.
    Giranda VL
    Structure; 1994 Aug; 2(8):695-8. PubMed ID: 7994569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle.
    Hadfield AT; Lee Wm; Zhao R; Oliveira MA; Minor I; Rueckert RR; Rossmann MG
    Structure; 1997 Mar; 5(3):427-41. PubMed ID: 9083115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.
    Rosenwirth B; Oren DA; Arnold E; Kis ZL; Eggers HJ
    Antiviral Res; 1995 Jan; 26(1):65-82. PubMed ID: 7741522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel benzonitrile analogue inhibits rhinovirus replication.
    Lacroix C; Querol-Audí J; Roche M; Franco D; Froeyen M; Guerra P; Terme T; Vanelle P; Verdaguer N; Neyts J; Leyssen P
    J Antimicrob Chemother; 2014 Oct; 69(10):2723-32. PubMed ID: 24948704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors.
    Fan SY; Zheng ZB; Mi CL; Zhou XB; Yan H; Gong ZH; Li S
    Bioorg Med Chem; 2009 Jan; 17(2):621-4. PubMed ID: 19091578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular dynamics investigation of the effect of an antiviral compound on human rhinovirus.
    Phelps DK; Post CB
    Protein Sci; 1999 Nov; 8(11):2281-9. PubMed ID: 10595531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
    Watson KG; Brown RN; Cameron R; Chalmers DK; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell DB; Reece PA; Ryan J; Stanislawski PC; Tucker SP; Wu WY; Barnard DL; Sidwell RW
    J Med Chem; 2003 Jul; 46(15):3181-4. PubMed ID: 12852746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of the multiple copy simultaneous search (MCSS) method to design a new class of picornavirus capsid binding drugs.
    Joseph-McCarthy D; Hogle JM; Karplus M
    Proteins; 1997 Sep; 29(1):32-58. PubMed ID: 9294865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules.
    Shih SR; Chen SJ; Hakimelahi GH; Liu HJ; Tseng CT; Shia KS
    Med Res Rev; 2004 Jul; 24(4):449-74. PubMed ID: 15170592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human rhinovirus 14 complexed with fragments of active antiviral compounds.
    Bibler-Muckelbauer JK; Kremer MJ; Rossmann MG; Diana GD; Dutko FJ; Pevear DC; McKinlay MA
    Virology; 1994 Jul; 202(1):360-9. PubMed ID: 8009848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human rhinovirus 3 at 3.0 A resolution.
    Zhao R; Pevear DC; Kremer MJ; Giranda VL; Kofron JA; Kuhn RJ; Rossmann MG
    Structure; 1996 Oct; 4(10):1205-20. PubMed ID: 8939746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
    Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
    J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.
    Diana GD; Kowalczyk P; Treasurywala AM; Oglesby RC; Pevear DC; Dutko FJ
    J Med Chem; 1992 Mar; 35(6):1002-8. PubMed ID: 1313108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity.
    Andries K; Dewindt B; Snoeks J; Wouters L; Moereels H; Lewi PJ; Janssen PA
    J Virol; 1990 Mar; 64(3):1117-23. PubMed ID: 2154596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.